Tuesday, September 10, 2019 3:13:10 PM
I can admit I made a mistake in mixing up Kymriah with the Juno drug.
You on the other refuse to admit your mistake that asserted neither was approved and both were behind NWBO in development.
KITE was clearly father along. One can not answer the JUNO question because neither they nor NWBO has made it to the finish line yet and nobody knows exactly where they were. I will bet on JUNO though, just like Cellgene did.
You tried to switch to GBM specifically, but that was not the conversation. The thread originated with BP buyouts, and that was not specific to GMB.
And as of today, the CAR-Ts are further along than path in most solid tumors. NSCLC, BC, Ovarian and a few others. While NWBO spins "pedal to the metal" w/o advancing a single non brain trial in about 5 years.
You on the other refuse to admit your mistake that asserted neither was approved and both were behind NWBO in development.
KITE was clearly father along. One can not answer the JUNO question because neither they nor NWBO has made it to the finish line yet and nobody knows exactly where they were. I will bet on JUNO though, just like Cellgene did.
You tried to switch to GBM specifically, but that was not the conversation. The thread originated with BP buyouts, and that was not specific to GMB.
And as of today, the CAR-Ts are further along than path in most solid tumors. NSCLC, BC, Ovarian and a few others. While NWBO spins "pedal to the metal" w/o advancing a single non brain trial in about 5 years.
Team Z lives on!
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
